5 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
Follow dilmapimod: new trials by email Literature Review of dilmapimod trials Research Report on dilmapimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain SB681323, Placebo - Pain, Neuropathic | Phase 2 | Completed | GlaxoSmithKline | 50 | 2006-08-30 | 2017-08-22 |
| A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention SB-681323 - Coronary Heart Disease | Phase 2 | Completed | GlaxoSmithKline | 80 | 2006-03-01 | 2012-06-04 |
| SB-681323 In Subjects With Rheumatoid Arthritis SB-681323 - Arthritis, Rheumatoid | Phase 2 | Completed | GlaxoSmithKline | 78 | 2005-11-01 | 2013-11-04 |
| Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD) SB681323 - Pulmonary Disease, Chronic Obstructive, Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | GlaxoSmithKline | 82 | 2005-07-01 | 2012-06-04 |
| A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis Prednisolone, SB-681323 - Arthritis, Rheumatoid | Phase 2 | Completed | GlaxoSmithKline | 77 | 2005-06-21 | 2017-07-31 |
Arthritis, Rheumatoid (2) · Atherosclerosis (1) · Coronary Disease (1) · Inflammation (1) · Neuralgia (1) · Pulmonary Disease, Chronic Obstructive (1)
GlaxoSmithKline (5)
Germany (4) · United Kingdom (4) · Denmark (3) · Australia (2) · Poland (2) · Russia (2) · Finland (1) · France (1) · Hong Kong (1) · Italy (1) · Netherlands (1) · Norway (1) · Spain (1) · Sweden (1)